<PAGE>
------------------------------
------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported):
March 6, 1996
XYTRONYX, INC.
--------------------------------
(Exact name of registrant as specified in its charter)
Delaware
--------------------------------
(State or other jurisdiction of incorporation)
0-14838 36-3258753
------------------ ------------------------
(Commissioner File Number) (IRS Employer Identification Number)
6555 Nancy Ridge Drive
Suite 200
San Diego, California 92121
--------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (619) 550-3900
--------------
<PAGE>
Item 5. Other Events.
The News Release dated March 6, 1996 regarding letter of intent to
acquire option to purchase Binary Therapeutics, Inc., filed as Exhibit 99.47
hereto, is hereby incorporated into this Report by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) EXHIBITS. The following exhibit accompanies this Report:
Exhibit
Number Exhibit Description
------ -------------------
99.47 News Release dated March 6, 1996 regarding letter of intent
to acquire option to purchase Binary Therapeutics, Inc
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
XYTRONYX, INC.
By: /s/ DALE SANDER
----------------------------
Dale Sander
Chief Financial Officer
Date: March 12, 1996
2
<PAGE>
INDEX TO EXHIBITS
Exhibit Sequentially
Number Description of Exhibit Numbered Page
- ------ ---------------------- -------------
99.47 News Release dated March 6, 1996 regarding letter
of intent to acquire option to purchase Binary
Therapeutics, Inc
3
<PAGE>
[LETTERHEAD]
FOR IMMEDIATE RELEASE
CONTACT: Dale A. Sander, Chief Financial Officer
Larry O. Bymaster, Chief Executive Officer
(619) 550-3900
- --------------------------------------------------------------------------------
XYTRONYX, INC. ANNOUNCES LETTER OF INTENT REGARDING OPTION TO PURCHASE BINARY
THERAPEUTICS, INC.
SAN DIEGO, CA, March 6, 1996 -- Xytronyx, Inc. (AMEX: XYX) today announced that
it has entered into a letter of intent defining the general terms under which it
expects to acquire an option to purchase Binary Therapeutics, Inc., a
Massachusetts-based company. Xytronyx anticipates finalizing a definitive
option agreement within approximately one month subject to approval by the
shareholders of Binary Therapeutics
Binary Therapeutics holds certain proprietary technologies in the area of
photodynamic therapy ("PDT") and boron neutron capture therapy ("BNCT"), both of
which are expected to rely upon the combined use of a drug compound and an
energy source to treat certain cancers.
Under the proposed terms of the option agreement, Xytronyx will assist Binary
Therapeutics with certain product development efforts and in exchange will
receive a one-year option to acquire Binary Therapeutics. Xytronyx indicated
that any additional information relating to the terms of the option will be
disclosed after completion of the final option agreement.
Mr. Larry Bymaster, Xytronyx Chairman, stated that "we are pleased to have
initiated a relationship with Binary Therapeutics and look forward to
participating in this opportunity."
Dr. Joseph Chang, the Chief Executive Officer of Binary Therapeutics, stated
that the company "expects this collaboration to accelerate our progress in
bringing these important therapies to market."
